TXG
10x Genomics, Inc.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q4 2021 | 19Q | $167 | $21 | -87% |
| Renaissance Technologies re-entered | Q3 2024(8Q snapshot) | 7Q | $20 | $21 | +5% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $20 | $21 | +9% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $20 | $21 | +9% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $20 | $21 | +9% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $20 | $21 | +9% |
| D.E. Shaw | Q1 2025(8Q snapshot) | 5Q | $12 | $21 | +74% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management | Q4 2024 | Q1 2025 | → $12 | -13% |
| Duquesne Family Office | Q4 2022 | Q1 2023 | → $45 | +15% |
| D1 Capital Partners 2× in & out | Q1 2022 | Q2 2022 | → $46 | -48% |
| Maverick Capital | Q1 2021 | Q4 2021 | → $158 | -18% |
| Third Point | Q4 2020 | Q1 2021 | → $192 | +39% |
| Viking Global Investors | Q4 2019 | Q1 2020 | → $87 | +42% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at 10x Genomics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.
- Form 40001610717-26-000196Jun 8, 2026
- Form 40001610717-26-000195Jun 8, 2026
- Form 40001610717-26-000194Jun 8, 2026
- Form 40001610717-26-000193Jun 8, 2026
- Form 40001610717-26-000192Jun 8, 2026
- Form 40001610717-26-000191Jun 8, 2026
- Form 40001610717-26-000164May 27, 2026
- Form 40001610717-26-000163May 27, 2026
- Form 40001610717-26-000162May 27, 2026
- Form 40001610717-26-000145Apr 16, 2026
- Form 40001610717-26-000134Mar 25, 2026
- Form 40001610717-26-000086Mar 4, 2026
- Form 40001610717-26-000077Mar 2, 2026
- Form 40001610717-26-000076Mar 2, 2026
- Form 40001610717-26-000075Mar 2, 2026
Fundamentals
XBRL · 10x Genomics, Inc.Annual figures sourced directly from 10x Genomics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for 10x Genomics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 8, 2026
- 10-QQuarterly reportMay 8, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 24, 2026
- 10-KAnnual reportFeb 13, 2026
- 8-KMaterial eventFeb 12, 2026
- 8-KMaterial eventJan 12, 2026
- 8-KMaterial eventNov 14, 2025
- 10-QQuarterly reportNov 7, 2025
- 8-KMaterial eventNov 6, 2025
- 10-QQuarterly reportAug 8, 2025
- 8-KMaterial eventAug 7, 2025
- 8-KMaterial eventJun 5, 2025
- 8-KMaterial eventMay 14, 2025
- 10-QQuarterly reportMay 9, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q1 2026 | open | $19 | $21 | +15% |
| Bridgewater Associates | Q1 2026 | open | $18 | $31 | +69% |
| D.E. Shaw | Q1 2025 | open | $12 | $21 | +74% |
| Renaissance Technologies | Q1 2025 | open | $12 | $21 | +80% |
| Point72 Asset Management | Q4 2024 | Q1 2025 | $14 | $12 | -13% |
| Citadel Advisors | Q3 2024 | Q4 2025 | $20 | $16 | -20% |
| Two Sigma Investments | Q3 2024 | open | $20 | $21 | +9% |
| AQR Capital Management | Q3 2024 | open | $20 | $21 | +9% |
| Millennium Management | Q3 2024 | open | $20 | $21 | +9% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $20 | $15 | -27% |
| Bridgewater Associates | Q1 2023 | Q2 2023 | $45 | $53 | +18% |
| Duquesne Family Office | Q4 2022 | Q1 2023 | $39 | $45 | +15% |
| Bridgewater Associates | Q2 2022 | Q4 2022 | $48 | $38 | -21% |
| D1 Capital Partners | Q1 2022 | Q2 2022 | $89 | $46 | -48% |
| Bridgewater Associates | Q4 2021 | Q1 2022 | $167 | $89 | -46% |
| D1 Capital Partners | Q1 2021 | Q2 2021 | $192 | $144 | -25% |
| Maverick Capital | Q1 2021 | Q4 2021 | $192 | $158 | -18% |
| Third Point | Q4 2020 | Q1 2021 | $139 | $192 | +39% |
| Viking Global Investors | Q4 2019 | Q1 2020 | $61 | $87 | +42% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.